BRCA1 encodes a large nuclear protein that helps maintain genomic stability by coordinating the repair of DNA double-strand breaks through homologous recombination, and it also regulates transcription and the cell cycle. It acts as a tumor suppressor, working with proteins such as RAD51, BRCA2, BARD1, and PALB2 to preserve genome integrity. Inherited alterations in BRCA1 cause hereditary breast and ovarian cancer syndrome, with elevated risks of breast, ovarian, prostate, and pancreatic cancers, and biallelic loss underlies a rare form of Fanconi anemia. Because BRCA1-driven tumors rely on impaired DNA repair, they are treatable with PARP inhibitors.
BRCA1 encodes a tumor suppressor whose loss-of-function germline alterations drive hereditary breast and ovarian cancer syndrome through impaired DNA double-strand-break repair, and this exon 11 missense substitution p.Gly834Glu falls outside the protein's clinically important functional domains.
BP1 strong (met): p.Gly834Glu is a missense outside all clinically important BRCA1 domains (RING 2-101, coiled-coil 1391-1424, BRCT 1650-1857) with SpliceAI max delta 0.001, indicating no predicted splice impact.
